BioRestorative Therapies (BRTXQ) Stock Price, News & Analysis

Company Overview

BioRestorative Therapies, Inc. is a biotechnology company dedicated to developing and commercializing cell-based regenerative medicine solutions. The company focuses on advancing therapies designed to repair or replace damaged tissues and organs through the use of proprietary human cell lines. Its mission is to address unmet medical needs in areas such as respiratory distress, cardiac repair, and orthopedic applications by leveraging the regenerative capacity of specialized cells.

The company’s pipeline includes multiple preclinical and clinical-stage programs. One leading candidate, BRTX-100, is an allogeneic mesenchymal cell therapy targeting acute respiratory distress syndrome (ARDS) and other inflammatory lung conditions. Additional programs are exploring applications in congenital heart disease, intervertebral disc regeneration and orthopedic conditions, each utilizing differentiated cell populations optimized for specific tissue repair processes.

BioRestorative employs a proprietary automated cell manufacturing platform designed to ensure consistent cell quality and scalability. This platform integrates controlled bioreactor systems with advanced process analytics to support large-scale production under Good Manufacturing Practice (GMP) standards. The company’s research and manufacturing facilities are based in Boca Raton, Florida, and it maintains strategic collaborations with academic institutions and contract development organizations to expand its technological capabilities and geographic reach.

Founded in 2009, BioRestorative Therapies has evolved from a research-focused startup into a publicly traded entity on the OTC Markets (OTCMKTS:BRTXQ). The leadership team is spearheaded by Chief Executive Officer Frank H. Grillo, whose background in biopharmaceutical development has guided the company through key regulatory milestones and manufacturing scale-up initiatives. Moving forward, BioRestorative continues to pursue partnerships and funding opportunities aimed at advancing its regenerative medicine programs toward clinical and commercial success.

Key Stats

• Today's Range: $1.58 to $1.63
• 50-Day Range: $1.52 to $2.00
• 52-Week Range: $0.00 to $0.06
• Volume: 26,253 shs
• Average Volume: 62.17 million shs
• Market Capitalization: $2.61 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BRTXQ Stock Analysis - Frequently Asked Questions

How have BRTXQ shares performed this year?

BioRestorative Therapies' stock was trading at $1.43 at the beginning of 2025. Since then, BRTXQ stock has increased by 11.2% and is now trading at $1.59.

How do I buy shares of BioRestorative Therapies?

Shares of BRTXQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Miscellaneous Health & Allied Services
• Sub-Industry: Healthcare
• Current Symbol: OTCMKTS:BRTXQ
• CIK: 1505497
• Web: www.biorestorative.com
• Phone: 631-760-8100
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $110 thousand
• Price / Sales: 23,700.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.68) per share
• Price / Book: -2.34

Miscellaneous

• Outstanding Shares: 1,639,626,000
• Free Float: N/A
• Market Cap: $2.61 billion
• Optionable: Not Optionable
• Beta: 102.36